Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates German biotechnology firm BioNTech has partnered with Pfizer to jointly develop and distribute a potential mRNA-based Covid-19 vaccine.
The parties have implemented a material transfer and collaboration agreement to begin working. This agreement expands the research and development (R&D) alliance signed by the companies in 2018 to develop mRNA-based vaccines against influenza.
With the latest collaboration, the companies aim to speed-up the development of BioNTech’s BNT162 as a potential Covid-19 vaccine.
The candidate should advance into clinical testing next month. Pfizer development & medical worldwide research president Mikael Dolsten said: “We